癌症患者导管相关上肢深静脉血栓的管理:系统综述与荟萃分析
该系统综述与荟萃分析检索MEDLINE、Embase、Scopus和CENTRAL至2023年6月2日,纳入29项研究(N=2,836),评估癌症合并导管相关上肢深静脉血栓患者的复发静脉血栓栓塞和大出血发生率。汇总3个月复发静脉血栓栓塞率为0.56%(95%CI 0.10%-3.01%;I²=0%),3个月大出血率为2.34%(95%CI 1.14%-4.76%;I²=0%)。超过3个月的事件率因高异质性未能合并。
要点
- 癌症合并导管相关上肢深静脉血栓患者3个月复发静脉血栓栓塞汇总率为0.56%。
- 同一人群3个月大出血汇总率为2.34%。
- 超过3个月的管理与报告存在显著异质性,事件率未能合并。
核心结论
- 癌症合并导管相关上肢深静脉血栓患者在最初3个月内复发静脉血栓栓塞率相对较低,大出血事件率为中等。
- 3个月后的管理与报告存在显著异质性。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Scopus和CENTRAL从建库至2023年6月2日。
- 纳入29项研究(N=2,836),其中5项为前瞻性研究。
- 主要疗效结局为复发静脉血栓栓塞,主要安全性结局为大出血;采用随机效应模型汇总结局发生率(含95%CI)。
主要发现
- 随访时间和抗凝治疗差异很大;主要长期抗凝药物为低分子量肝素,其次为直接口服抗凝药。
- 14项研究(N=1,128)汇总的3个月复发静脉血栓栓塞率为0.56%(95%CI 0.10%-3.01%;I²=0%)。
- 10项研究(N=834)汇总的3个月大出血率为2.34%(95%CI 1.14%-4.76%;I²=0%)。
- 超过3个月的事件率因高异质性未能合并。
- 所有研究均存在严重偏倚风险。
局限性
- 随访时间和抗凝治疗差异很大。
- 超过3个月的事件率因高异质性未能合并。
- 所有研究均存在严重偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with cancer commonly require a central venous catheter, which is associated with an increased risk of venous thromboembolism (VTE). Despite the frequent occurrence, the optimal anticoagulation management and outcomes for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT) are unclear. OBJECTIVE: We performed a systematic review and meta-analysis to evaluate the rates of recurrent VTE and bleeding in patients with cancer and catheter-related upper extremity DVT. METHODS: We searched MEDLINE, Embase, Scopus, and CENTRAL from inception to June 2, 2023. The primary efficacy outcome was recurrent VTE, and the primary safety outcome was major bleeding. The incidence rates (with 95% CI) of outcomes were pooled using random effects model. RESULTS: We included 29 studies (N = 2,836), among which 5 were prospective. The duration of follow-up and anticoagulation varied considerably. The main long-term anticoagulant used was low molecular weight heparin, followed by direct oral anticoagulants. The pooled 3-month recurrent VTE rate from 14 studies (N = 1,128) was 0.56% (95% CI, 0.10%-3.01%; I2 = 0%). The pooled 3-month major bleeding rate from 10 studies (N = 834) was 2.34% (95% CI, 1.14%-4.76%; I2 = 0%). We were unable to pool event rates beyond 3 months, given high heterogeneity. All studies had serious risk of bias. CONCLUSIONS: Our study demonstrated a relatively low rate of recurrent VTE and moderate rate of major bleeding events within the first 3 months in patients with cancer and catheter-related upper extremity DVT. However, there was significant heterogeneity in the management and reporting after 3 months.
引用
- Wang TF, Kou R, Carrier M, et al. Management of catheter-related upper extremity deep vein thrombosis in patients with cancer: a systematic review and meta-analysis. J Thromb Haemost. 2023. PMID: 38065528. doi:10.1016/j.jtha.2023.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。